DSGN vs. ZVRA, VERU, GTHX, ELYM, TELO, TRVI, LFCR, ALIM, ACRV, and PRLD
Should you be buying Design Therapeutics stock or one of its competitors? The main competitors of Design Therapeutics include Zevra Therapeutics (ZVRA), Veru (VERU), G1 Therapeutics (GTHX), Eliem Therapeutics (ELYM), Telomir Pharmaceuticals (TELO), Trevi Therapeutics (TRVI), Lifecore Biomedical (LFCR), Alimera Sciences (ALIM), Acrivon Therapeutics (ACRV), and Prelude Therapeutics (PRLD). These companies are all part of the "pharmaceutical preparations" industry.
Zevra Therapeutics (NASDAQ:ZVRA) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, dividends and risk.
Zevra Therapeutics has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Zevra Therapeutics had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 14 mentions for Zevra Therapeutics and 12 mentions for Design Therapeutics. Zevra Therapeutics' average media sentiment score of 0.64 beat Design Therapeutics' score of 0.38 indicating that Design Therapeutics is being referred to more favorably in the news media.
Design Therapeutics has a net margin of 0.00% compared to Design Therapeutics' net margin of -167.69%. Zevra Therapeutics' return on equity of -22.82% beat Design Therapeutics' return on equity.
Zevra Therapeutics presently has a consensus price target of $19.50, suggesting a potential upside of 287.67%. Design Therapeutics has a consensus price target of $6.60, suggesting a potential upside of 38.36%. Given Design Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Zevra Therapeutics is more favorable than Design Therapeutics.
Zevra Therapeutics received 3 more outperform votes than Design Therapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Zevra Therapeutics an outperform vote while only 34.48% of users gave Design Therapeutics an outperform vote.
35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by insiders. Comparatively, 25.7% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Zevra Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the S&P 500. Comparatively, Design Therapeutics has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500.
Summary
Zevra Therapeutics beats Design Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Design Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DSGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Design Therapeutics Competitors List
Related Companies and Tools
